BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

With a spate of new and expanded deals this year, Takeda is not letting its $62 billion dollar takeout of Shire slow its transformation from a traditional small molecule company to a home for edgier,...
BC Extra | May 16, 2019
Clinical News

May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven

Abstracts were released late Wednesday ahead of the American Society of Clinical Oncology meeting starting May 31 in Chicago. See below for BioCentury's first round of Quick Takes on selected abstracts. Iovance gains on 44%...
BioCentury | Sep 28, 2018
Finance

Activating Akrevia

Akrevia Therapeutics LLC parlayed preclinical proof-of-concept data from its tumor-activated therapies into a $30 million series A round co-led by Atlas Venture and F-Prime Capital Partners. Akrevia, which emerged from stealth on Sept. 27, uses...
BC Week In Review | Sep 28, 2018
Financial News

F-Prime, Atlas lead Akrevia's $30M series A

Immunotherapy company Akrevia Therapeutics LLC (Cambridge, Mass.) launched on Sept. 27 with a $30 million series A round co-led by F-Prime Capital Partners and Atlas Venture. Akrevia’s Aklusion platform enables biological molecules such as antibodies,...
BC Extra | Sep 27, 2018
Financial News

F-Prime, Atlas lead Akrevia's $30M series A

Immunotherapy company Akrevia Therapeutics LLC (Cambridge, Mass.) launched with a $30 million series A round co-led by F-Prime Capital Partners and Atlas Venture. Akrevia’s Aklusion platform enables biological molecules such as antibodies, cytokines and chemokines...
BC Week In Review | Sep 14, 2018
Company News

Takeda to move U.S. headquarters to Boston area

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) will move its U.S. headquarters from Deerfield, Ill., to a to-be-determined site in the greater Boston area after its planned acquisition of Shire plc (LSE:SHP; NASDAQ:SHPG) closes next half. Takeda...
BC Extra | Sep 12, 2018
Company News

Takeda to move U.S. headquarters to Boston

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) will move its U.S. headquarters from Deerfield, Ill., to a to-be-determined site in the greater Boston area after its planned acquisition of Shire plc (LSE:SHP; NASDAQ:SHPG) closes next half. Takeda...
BC Extra | Jul 25, 2018
Company News

Management Tracks: Albireo, ObsEva

Pediatric liver disease company Albireo Pharma Inc. (NASDAQ:ALBO) said CMO Paresh Soni will step down. He is succeeded by Patrick Horn, who was SVP of medical and clinical development at Orphan Technologies Ltd. (Rapperswil, Switzerland)....
BC Week In Review | Jun 1, 2018
Company News

Ironwood shareholders vote to keep board intact

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said its shareholders re-elected all three of its preferred board director nominees during its annual shareholder meeting. Alex Denner, who holds about a 2.2% stake in Ironwood and is chief investment...
BC Extra | May 31, 2018
Company News

Ironwood shareholders opt to keep board intact

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said its shareholders re-elected all three of its preferred board director nominees during its annual shareholder meeting. Alex Denner, who holds about a 2.2% stake in Ironwood and is chief investment...
Items per page:
1 - 10 of 689
BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

With a spate of new and expanded deals this year, Takeda is not letting its $62 billion dollar takeout of Shire slow its transformation from a traditional small molecule company to a home for edgier,...
BC Extra | May 16, 2019
Clinical News

May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven

Abstracts were released late Wednesday ahead of the American Society of Clinical Oncology meeting starting May 31 in Chicago. See below for BioCentury's first round of Quick Takes on selected abstracts. Iovance gains on 44%...
BioCentury | Sep 28, 2018
Finance

Activating Akrevia

Akrevia Therapeutics LLC parlayed preclinical proof-of-concept data from its tumor-activated therapies into a $30 million series A round co-led by Atlas Venture and F-Prime Capital Partners. Akrevia, which emerged from stealth on Sept. 27, uses...
BC Week In Review | Sep 28, 2018
Financial News

F-Prime, Atlas lead Akrevia's $30M series A

Immunotherapy company Akrevia Therapeutics LLC (Cambridge, Mass.) launched on Sept. 27 with a $30 million series A round co-led by F-Prime Capital Partners and Atlas Venture. Akrevia’s Aklusion platform enables biological molecules such as antibodies,...
BC Extra | Sep 27, 2018
Financial News

F-Prime, Atlas lead Akrevia's $30M series A

Immunotherapy company Akrevia Therapeutics LLC (Cambridge, Mass.) launched with a $30 million series A round co-led by F-Prime Capital Partners and Atlas Venture. Akrevia’s Aklusion platform enables biological molecules such as antibodies, cytokines and chemokines...
BC Week In Review | Sep 14, 2018
Company News

Takeda to move U.S. headquarters to Boston area

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) will move its U.S. headquarters from Deerfield, Ill., to a to-be-determined site in the greater Boston area after its planned acquisition of Shire plc (LSE:SHP; NASDAQ:SHPG) closes next half. Takeda...
BC Extra | Sep 12, 2018
Company News

Takeda to move U.S. headquarters to Boston

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) will move its U.S. headquarters from Deerfield, Ill., to a to-be-determined site in the greater Boston area after its planned acquisition of Shire plc (LSE:SHP; NASDAQ:SHPG) closes next half. Takeda...
BC Extra | Jul 25, 2018
Company News

Management Tracks: Albireo, ObsEva

Pediatric liver disease company Albireo Pharma Inc. (NASDAQ:ALBO) said CMO Paresh Soni will step down. He is succeeded by Patrick Horn, who was SVP of medical and clinical development at Orphan Technologies Ltd. (Rapperswil, Switzerland)....
BC Week In Review | Jun 1, 2018
Company News

Ironwood shareholders vote to keep board intact

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said its shareholders re-elected all three of its preferred board director nominees during its annual shareholder meeting. Alex Denner, who holds about a 2.2% stake in Ironwood and is chief investment...
BC Extra | May 31, 2018
Company News

Ironwood shareholders opt to keep board intact

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said its shareholders re-elected all three of its preferred board director nominees during its annual shareholder meeting. Alex Denner, who holds about a 2.2% stake in Ironwood and is chief investment...
Items per page:
1 - 10 of 689